<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Appl Thromb Hemost</journal-id><journal-id journal-id-type="iso-abbrev">Clin. Appl. Thromb. Hemost</journal-id><journal-id journal-id-type="publisher-id">CAT</journal-id><journal-id journal-id-type="hwp">spcat</journal-id><journal-title-group><journal-title>Clinical and Applied Thrombosis/Hemostasis</journal-title></journal-title-group><issn pub-type="ppub">1076-0296</issn><issn pub-type="epub">1938-2723</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage CA: Los Angeles, CA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6829969</article-id><article-id pub-id-type="pmid">31512486</article-id><article-id pub-id-type="doi">10.1177/1076029619875520</article-id><article-id pub-id-type="publisher-id">10.1177_1076029619875520</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Effect of CYP2C19 and Nongenetic Factors on Clopidogrel Responsiveness in
the MENA Region: A Systematic Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7667-2546</contrib-id><name><surname>Ali</surname><given-names>Zainab</given-names></name><degrees>Msc</degrees><xref ref-type="aff" rid="aff1-1076029619875520">1</xref></contrib><contrib contrib-type="author"><name><surname>Elewa</surname><given-names>Hazem</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1-1076029619875520">1</xref><xref ref-type="corresp" rid="corresp1-1076029619875520"/></contrib></contrib-group><aff id="aff1-1076029619875520">
<label>1</label>College of Pharmacy, Qatar University, Doha, Qatar</aff><author-notes><corresp id="corresp1-1076029619875520">Hazem Elewa, College of Pharmacy, Qatar University,
Doha 2713, Qatar. Email: <email>hazem.elewa@qu.edu.qa</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2019</year></pub-date><volume>25</volume><elocation-id>1076029619875520</elocation-id><history><date date-type="received"><day>2</day><month>7</month><year>2019</year></date><date date-type="accepted"><day>2</day><month>8</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder content-type="sage">SAGE Publications Inc. unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits
non-commercial use, reproduction and distribution of the work without further permission
provided the original work is attributed as specified on the SAGE and Open Access pages
(<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><p>Clopidogrel is the cornerstone antiplatelet used in the treatment and prevention of
thrombotic events. Some studies examined the effect of <italic>CYP2C19</italic>
polymorphism and nongenetic factors on clopidogrel response in the Middle East and North
Africa (MENA) region. However, the consistency among these studies is yet unknown. This
study aims to estimate the prevalence of <italic>CYP2C19</italic> genetic variants in MENA
region and to evaluate the effect of these variants as well as the nongenetic factors on
clopidogrel responsiveness. A systematic literature search was performed to identify
relevant articles. Only observational studies were included. A total of 20 studies in 8
different populations were included. The <italic>CYP2C19*2</italic> variant is the most
prevalent loss-of-function (LOF) allele in the MENA region (1.7%-35%). The frequency of
<italic>CYP2C19*17</italic> ranged from 5.3% to 26.9%. Of the 9 studies, 6 found an
association between carriers of at least 1 LOF allele and clopidogrel resistance. Older
age, high body mass index, females, and the use of calcium channel blockers were
associated with clopidogrel resistance as well. Association between the
<italic>CYP2C19*2</italic> allele and clopidogrel resistance is common among MENA
populations. Future studies should focus on having larger sample sizes to detect other
minor variant alleles and their effect on bleeding and cardiovascular outcomes.</p></abstract><kwd-group><kwd>clopidogrel resistance</kwd><kwd>loss-of-function allele</kwd><kwd>gain-of-function allele</kwd><kwd>genetic</kwd></kwd-group><funding-group><award-group id="award1-1076029619875520"><funding-source id="funding1-1076029619875520"><institution-wrap><institution>Hamad Medical Corporation</institution><institution-id>http://dx.doi.org/10.13039/100007833</institution-id></institution-wrap></funding-source><award-id rid="funding1-1076029619875520">IRGC-02-NI-052</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-1076029619875520"><title>Introduction</title><p>Clopidogrel is the most widely used P2Y12 blocker worldwide, especially in the prevention
of thrombotic events in patients with acute coronary syndrome (ACS) and/or stroke.<sup><xref rid="bibr1-1076029619875520" ref-type="bibr">1</xref><xref rid="bibr2-1076029619875520" ref-type="bibr"/>&#x02013;<xref rid="bibr3-1076029619875520" ref-type="bibr">3</xref></sup> Nevertheless, not all patients respond to clopidogrel therapy adequately. This
interpatient variability may compromise both efficacy and safety.<sup><xref rid="bibr4-1076029619875520" ref-type="bibr">4</xref></sup> Some recent studies postulated that clopidogrel has a narrow therapeutic window where
high on-treatment platelet reactivity (HTPR) is associated with thrombotic events while low
on-treatment platelet reactivity is associated with bleeding events.<sup><xref rid="bibr5-1076029619875520" ref-type="bibr">5</xref>,<xref rid="bibr6-1076029619875520" ref-type="bibr">6</xref></sup> Therefore, several studies have investigated genetic and nongenetic factors that may
be associated with clopidogrel response.<sup><xref rid="bibr7-1076029619875520" ref-type="bibr">7</xref>,<xref rid="bibr8-1076029619875520" ref-type="bibr">8</xref></sup>
</p><p>Clopidogrel is a thienopyridine prodrug metabolized primarily through
<italic>CYP2C19</italic> to form an active metabolite that selectively and irreversibly
blocks P2Y12 receptor.<sup><xref rid="bibr9-1076029619875520" ref-type="bibr">9</xref></sup> Most of the pharmacogenetic studies on clopidogrel have found an association between
<italic>CYP2C19</italic> genetic variants and response to clopidogrel.<sup><xref rid="bibr10-1076029619875520" ref-type="bibr">10</xref></sup> According to Clinical Pharmacogenetics Implementation Consortium Guidelines for
<italic>CYP2C19</italic> Genotype and Clopidogrel Therapy (CPIC), individuals are
categorized according to their <italic>CYP2C19</italic> genotype into ultra-rapid (*1/*17,
*17/*17), extensive (*1/*1), intermediate (*1/*2, *1/*3, *2/*17), and poor (*2/*2, *2/*3,
*3/*3) metabolizers.<sup><xref rid="bibr11-1076029619875520" ref-type="bibr">11</xref></sup> Based on the reduced efficacy reported for both <italic>CYP2C19</italic> intermediate
and poor metabolizers, CPIC recommends using an alternative antiplatelet treatment (eg,
prasugrel or ticagrelor) for patients in this category.<sup><xref rid="bibr11-1076029619875520" ref-type="bibr">11</xref></sup> Additionally, US Food and Drug Administration has put a black box warning regarding
<italic>CYP2C19</italic> poor metabolizers and the associated cardiovascular risk.<sup><xref rid="bibr12-1076029619875520" ref-type="bibr">12</xref></sup> In regard to the genetic variants, the most common loss-of-function (LOF) allele is
<italic>CYP2C19*2</italic>.<sup><xref rid="bibr13-1076029619875520" ref-type="bibr">13</xref></sup> Two meta-analyses indicated that patients carrying 1 copy of the
<italic>CYP2C19*2</italic> allele have increased risk of major cardiovascular adverse
events (MACE; hazard ratio [HR]: 1.55; 95% confidence interval [CI], 1.11-2.17) and stent
thrombosis (HR: 2.67; 95% CI, 1.69-4.22).<sup><xref rid="bibr14-1076029619875520" ref-type="bibr">14</xref>,<xref rid="bibr15-1076029619875520" ref-type="bibr">15</xref></sup> On the other hand, the most prevalent gain-of-function allele is
<italic>CYP2C19*17</italic>. A meta-analysis has found that <italic>CYP2C19*17</italic>
carriers had a significant protection against MACE in patients with coronary artery disease
compared with noncarriers (10.0% vs 11.9%; odds ratio [OR], 0.82; 95% CI, 0.72-0.94;
<italic>P</italic> = .005). However, <italic>CYP2C19*17</italic> carriers had also a
higher incidence of bleeding (8.0% vs 6.5%; OR, 1.25; 95% CI, 1.07-1.47; <italic>P</italic>
= .006).<sup><xref rid="bibr16-1076029619875520" ref-type="bibr">16</xref></sup> Lastly, some nongenetic factors, such as old age (&#x0003e;65 years), type 2 diabetes
mellitus, left ventricular dysfunction, and renal failure, were also found to affect
clopidogrel responsiveness.<sup><xref rid="bibr13-1076029619875520" ref-type="bibr">13</xref></sup>
</p><p>Middle East and North Africa (MENA) involves unique populations with diverse ethnicities
and genetic makeup due to the continuous migration in and out of its countries. This
diversity created a heavily admixed population of Asian, Caucasian, Arab, and African
Ancestry and made it important to have their own genetic studies. Thus, several studies from
different countries of MENA examined the effect of <italic>CYP2C19</italic> polymorphism and
nongenetic factors on clopidogrel response. Nevertheless, the consistency between these
studies is not very well known. Therefore, we aimed to systematically review studies
conducted in the MENA region to investigate the effect of genetic and nongenetic factors on
clopidogrel responsiveness and its impact on cardiovascular outcomes.</p></sec><sec sec-type="methods" id="section2-1076029619875520"><title>Methods</title><sec id="section3-1076029619875520"><title>Search Strategy</title><p>A search strategy was developed for each electronic database using a combination of
Medical Subject Heading (MeSH) and free-text terms to identify the relevant observational
studies with no date restrictions. The search was limited to articles published in English
language. The search started on March 2016 and was completed by the second week of April
2016.</p><p>PubMed, EMBASE, Scopus, Google-Scholar, PharmGKB (Pharmacogenomics Knowledge Base), and
HuGENet were searched using different MeSH (where appropriate) and key terms connected
with Boolean operators (AND/OR).</p><p>EMBASE has an advantage of refining the search by country, which was very helpful in our
case. The following are examples of combinations where both MeSH and key terms were used
to search PubMed:<list list-type="bullet"><list-item><p>Combination #1: &#x0201c;<italic>CYP2C19</italic>&#x0201d; AND &#x0201c;polymorphism&#x0201d; AND &#x0201c;Clopidogrel&#x0201d;</p></list-item><list-item><p>Combination #2: &#x0201c;Pharmacogenomics&#x0201d; AND &#x0201c;Clopidogrel&#x0201d;</p></list-item><list-item><p>Combination #3: &#x0201c;<italic>CYP2C19</italic>&#x0201d; AND &#x0201c;Clopidogrel&#x0201d; AND &#x0201c;Egypt&#x0201d;</p></list-item><list-item><p>Combination #4: ((&#x0201c;Cytochrome P-450 <italic>CYP2C19</italic>&#x0201d;[Mesh]) AND
&#x0201c;clopidogrel&#x0201d; [Supplementary Concept]) AND (&#x0201c;Acute Coronary
Syndrome/metabolism&#x0201d;[Mesh] OR &#x0201c;Acute Coronary Syndrome/therapy&#x0201d;[Mesh])</p></list-item><list-item><p>Combination #5: ((&#x0201c;Cytochrome P-450 <italic>CYP2C19</italic>&#x0201d;[Mesh]) AND
&#x0201c;clopidogrel&#x0201d; [Supplementary Concept]) AND &#x0201c;Platelet Function Tests&#x0201d;[Mesh]</p></list-item></list>
</p><p>Additionally, Google Scholar was also searched without any language or date limits to
identify gray literature. Furthermore, the reference lists of selected articles were
hand-searched to identify additional relevant articles that were missed in the search
strategy.</p><p>Our systematic review adhered to the PRISMA statements of reporting on systematic reviews
and was published in Prospero at <ext-link ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=64369">https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=64369</ext-link>
</p></sec><sec id="section4-1076029619875520"><title>Study Types</title><p>Observational studies were included (prospective, retrospective, or cross-sectional).
Reviews, letters, editorials, and commentaries were excluded from this review.</p></sec><sec id="section5-1076029619875520" sec-type="subjects"><title>Participants</title><p>Adults aged 18 years or older from the MENA region, with ACS who require percutaneous
coronary intervention (PCI) and/or coronary-artery bypass grafting (CABG), and starting or
continuing clopidogrel. Clopidogrel users for an indication other than cardiac indication,
such as stroke secondary prevention, were included as well.</p></sec><sec id="section6-1076029619875520"><title>Outcomes Measured</title><p>Studies that assessed the effect of <italic>CYP2C19</italic> polymorphism and/or
nongenetic factors on clopidogrel responsiveness (based on platelet reactivity unit
[PRU]/platelet inhibition/platelet aggregation and/or cardiovascular clinical outcomes)
were included in this systematic review.</p></sec><sec id="section7-1076029619875520"><title>Eligibility Criteria</title><p>To achieve the objectives of this systematic review, articles were included if they
fulfilled any of the following criteria:</p><p>For the prevalence of <italic>CYP2C19</italic> genetic polymorphism in MENA countries
without its impact on cardiovascular outcomes:</p><p>The study evaluated <italic>CYP2C19</italic> genetic polymorphism and their relevant
genotypes in a population from the MENA region (either healthy or diseased using
clopidogrel).</p><p>For the effect of <italic>CYP2C19</italic> genetic polymorphism and nongenetic factors on
clopidogrel responsiveness and its impact on cardiovascular outcomes in the MENA
region:<list list-type="order"><list-item><p>The study population included patients who had ACS (ST-elevation, non-ST-elevation
myocardial infarction, or unstable angina) or revascularization (any type of PCI or
CABG), with a consequent exposure to clopidogrel therapy (75 mg/d).</p></list-item><list-item><p>Patients taking clopidogrel for an indication other than cardiac indications, such
as stroke secondary prevention, were included.</p></list-item><list-item><p>The study assessed the effect of <italic>CYP2C19</italic> polymorphism and/or
nongenetic factors on clopidogrel responsiveness.</p></list-item><list-item><p>The clopidogrel responsiveness was assessed based on the PRU/platelet inhibition
and/or MACE/stroke/fatal or nonfatal stent thrombosis.</p></list-item><list-item><p>The primary definition of MACE was the composite of death (either all-cause or
cardiac), nonfatal myocardial infarction, and nonfatal stroke.<sup><xref rid="bibr17-1076029619875520" ref-type="bibr">17</xref></sup>
</p></list-item><list-item><p>These studies must be conducted on MENA region populations.</p></list-item></list>
</p></sec><sec id="section8-1076029619875520"><title>Study Selection</title><p>There were 2 screening phases for the articles according to the prespecified inclusion
and exclusion criteria. First, duplicates were removed and then title and abstract of the
articles were screened to determine whether they were irrelevant. In the second screening
phase, full text of the relevant articles was obtained and those that fulfilled the
inclusion criteria were included. There were 2 independent reviewers involved in the
screening process. Any disagreement was resolved by discussion and consensus.</p></sec><sec id="section9-1076029619875520"><title>Data Extraction</title><p>A specific data extraction tool was developed by the 2 authors and used to collect data
from the included articles. Extracted data were author and year of publication, sample
size, indication, population studied, cardiovascular risk factors (smoking, diabetes,
hypertensions, and dyslipidemia), clopidogrel-loading dose, clopidogrel maintenance dose
and duration, follow-up, outcomes reported, genetic and nongenetic factors studied, and
main results. For each eligible study, data of interest were extracted by 1 researcher. To
ensure quality and accuracy, each data collection form was double-checked and verified by
the other researcher.</p></sec><sec id="section10-1076029619875520"><title>Quality Assessment</title><p>For assessing the quality of the included studies, the National Heart, Lung, and Blood
Institute quality assessment tool for observational cohort and cross-sectional studies was used.<sup><xref rid="bibr18-1076029619875520" ref-type="bibr">18</xref></sup>
</p></sec></sec><sec sec-type="results" id="section11-1076029619875520"><title>Results</title><sec id="section12-1076029619875520"><title>Selection of Studies</title><p>The search retrieved 4679 articles, 2070 from PubMed, 1121 from EMBASE, 975 from Scopus,
413 from PharmGKB, and 100 from HuGENet. Based on the inclusion criteria, a total of 20
studies were included in this systematic review. <xref ref-type="fig" rid="fig1-1076029619875520">Figure 1</xref> shows the flowchart of the included studies.
Twenty-eight studies were eligible for full-text screening, 6 studies were excluded for
studying patients outside the MENA region,<sup><xref rid="bibr13-1076029619875520" ref-type="bibr">13</xref>,<xref rid="bibr19-1076029619875520" ref-type="bibr">19</xref><xref rid="bibr20-1076029619875520" ref-type="bibr"/><xref rid="bibr21-1076029619875520" ref-type="bibr"/><xref rid="bibr22-1076029619875520" ref-type="bibr"/>&#x02013;<xref rid="bibr23-1076029619875520" ref-type="bibr">23</xref></sup> and 2 papers were excluded because they were reviews.<sup><xref rid="bibr24-1076029619875520" ref-type="bibr">24</xref>,<xref rid="bibr25-1076029619875520" ref-type="bibr">25</xref></sup> The 20 studies reviewed were from 8 different countries, including Egypt, Jordan,
Iran, Lebanon, Turkey, Saudi Arabia, Palestine, and Qatar.</p><fig id="fig1-1076029619875520" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>PRISMA flowchart of included studies.</p></caption><graphic xlink:href="10.1177_1076029619875520-fig1"/></fig></sec><sec id="section13-1076029619875520"><title>Prevalence of Explored Genetic Variants</title><p>Minor allele frequency (MAF) was used to estimate the prevalence of
<italic>CYP2C19</italic> genetic variants. Minor allele frequencies of
<italic>CYP2C19</italic> genetic variants are presented in <xref rid="table1-1076029619875520" ref-type="table">Table 1</xref>. <italic>CYP2C19*1</italic> variant
(wild-type) had the highest frequencies among all populations, followed by the *2, *17,
and *3. Minor allele frequency of *3 and *17 was not explored in all the studies. The
<italic>CYP2C19*2</italic> variant was the most prevalent LOF allele in the MENA region
and was highest among Jordanian (35%)<sup><xref rid="bibr26-1076029619875520" ref-type="bibr">26</xref></sup> and lowest among Turkish (1.7%).<sup><xref rid="bibr27-1076029619875520" ref-type="bibr">27</xref></sup> Eight studies estimated the prevalence of <italic>CYP2C19*2</italic> in Iranian
populations. Five of these studies had similar MAF of *2 allele (13%),<sup><xref rid="bibr28-1076029619875520" ref-type="bibr">28</xref><xref rid="bibr29-1076029619875520" ref-type="bibr"/><xref rid="bibr30-1076029619875520" ref-type="bibr"/><xref rid="bibr31-1076029619875520" ref-type="bibr"/>&#x02013;<xref rid="bibr32-1076029619875520" ref-type="bibr">32</xref></sup> but 2 studies had higher frequencies (27.9% and 19.1%).<sup><xref rid="bibr27-1076029619875520" ref-type="bibr">27</xref>,<xref rid="bibr33-1076029619875520" ref-type="bibr">33</xref></sup> The prevalence of <italic>CYP2C19*2</italic> varied among Saudi Arabians, with a
range of 8.2% to 30%.<sup><xref rid="bibr34-1076029619875520" ref-type="bibr">34</xref>,<xref rid="bibr35-1076029619875520" ref-type="bibr">35</xref></sup>
</p><table-wrap id="table1-1076029619875520" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Minor Allele Frequency of <italic>CYP2C19</italic> Genetic Variants.</p></caption><alternatives><graphic xlink:href="10.1177_1076029619875520-table1"/><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Population</th><th rowspan="2" colspan="1">Sample Size</th><th colspan="4" rowspan="1">
<italic>CYP2C19</italic> Alleles</th></tr><tr><th rowspan="1" colspan="1">*1</th><th rowspan="1" colspan="1">*2 (rs4244285)</th><th rowspan="1" colspan="1">*3 (rs4986893) or (rs57081121)</th><th rowspan="1" colspan="1">*17 (rs12248560)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Iranian<sup><xref rid="bibr28-1076029619875520" ref-type="bibr">28</xref></sup>
</td><td rowspan="1" colspan="1">691</td><td rowspan="1" colspan="1">87.10%</td><td rowspan="1" colspan="1">12.30%</td><td rowspan="1" colspan="1">0.50%</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Turkish<sup><xref rid="bibr41-1076029619875520" ref-type="bibr">41</xref></sup>
</td><td rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1">83%</td><td rowspan="1" colspan="1">17%</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Saudi Arabians<sup><xref rid="bibr34-1076029619875520" ref-type="bibr">34</xref></sup>
</td><td rowspan="1" colspan="1">192</td><td rowspan="1" colspan="1">64.9%</td><td rowspan="1" colspan="1">8.20%</td><td rowspan="1" colspan="1">0%</td><td rowspan="1" colspan="1">26.90%</td></tr><tr><td rowspan="1" colspan="1">Egyptian<sup><xref rid="bibr36-1076029619875520" ref-type="bibr">36</xref></sup>
</td><td rowspan="1" colspan="1">190</td><td rowspan="1" colspan="1">70.15%</td><td rowspan="1" colspan="1">12.6%</td><td rowspan="1" colspan="1">0.25%</td><td rowspan="1" colspan="1">17%</td></tr><tr><td rowspan="1" colspan="1">Iranian<sup><xref rid="bibr29-1076029619875520" ref-type="bibr">29</xref></sup>
</td><td rowspan="1" colspan="1">200</td><td rowspan="1" colspan="1">86.00%</td><td rowspan="1" colspan="1">14.00%</td><td rowspan="1" colspan="1">0%</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Iranian<sup><xref rid="bibr30-1076029619875520" ref-type="bibr">30</xref></sup>
</td><td rowspan="1" colspan="1">150</td><td rowspan="1" colspan="1">86.73%</td><td rowspan="1" colspan="1">13.00%</td><td rowspan="1" colspan="1">1.00%</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Iranian<sup><xref rid="bibr42-1076029619875520" ref-type="bibr">42</xref></sup>
</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">72.10%</td><td rowspan="1" colspan="1">27.90%</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Iranian<sup><xref rid="bibr31-1076029619875520" ref-type="bibr">31</xref></sup>
</td><td rowspan="1" colspan="1">112</td><td rowspan="1" colspan="1">88.99%</td><td rowspan="1" colspan="1">10.09%</td><td rowspan="1" colspan="1">0.91%</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Iranian<sup><xref rid="bibr32-1076029619875520" ref-type="bibr">32</xref></sup>
</td><td rowspan="1" colspan="1">180</td><td rowspan="1" colspan="1">65.30%</td><td rowspan="1" colspan="1">13.10%</td><td rowspan="1" colspan="1">0%</td><td rowspan="1" colspan="1">21.60%</td></tr><tr><td rowspan="1" colspan="1">Lebanese<sup><xref rid="bibr37-1076029619875520" ref-type="bibr">37</xref></sup>
</td><td rowspan="1" colspan="1">161</td><td rowspan="1" colspan="1">86.30%</td><td rowspan="1" colspan="1">13.40%</td><td rowspan="1" colspan="1">0.30%</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Palestinian and Turkish<sup><xref rid="bibr38-1076029619875520" ref-type="bibr">38</xref></sup>
</td><td rowspan="1" colspan="1">200</td><td rowspan="1" colspan="1">90.5% in Palestinians and 86.5% in Turkish</td><td rowspan="1" colspan="1">9.5% in Palestinian and 13.5% in Turkish</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Saudi Arabians<sup><xref rid="bibr39-1076029619875520" ref-type="bibr">39</xref></sup>
</td><td rowspan="1" colspan="1">201</td><td rowspan="1" colspan="1">62.90%</td><td rowspan="1" colspan="1">11.20%</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">25.70%</td></tr><tr><td rowspan="1" colspan="1">Saudi Arabians<sup><xref rid="bibr40-1076029619875520" ref-type="bibr">40</xref></sup>
</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">85.3%</td><td rowspan="1" colspan="1">10.37%</td><td rowspan="1" colspan="1">4.4%</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Turkish<sup><xref rid="bibr43-1076029619875520" ref-type="bibr">43</xref></sup>
</td><td rowspan="1" colspan="1">347</td><td rowspan="1" colspan="1">89.50%</td><td rowspan="1" colspan="1">5.1%</td><td rowspan="1" colspan="1">0.1%</td><td rowspan="1" colspan="1">5.30%</td></tr><tr><td rowspan="1" colspan="1">Saudi Arabians<sup><xref rid="bibr35-1076029619875520" ref-type="bibr">35</xref></sup>
</td><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1">70%</td><td rowspan="1" colspan="1">30%</td><td rowspan="1" colspan="1">0%</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Jordanian<sup><xref rid="bibr26-1076029619875520" ref-type="bibr">26</xref></sup>
</td><td rowspan="1" colspan="1">270</td><td rowspan="1" colspan="1">65%</td><td rowspan="1" colspan="1">35%</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Turkish<sup><xref rid="bibr27-1076029619875520" ref-type="bibr">27</xref></sup>
</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">92%</td><td rowspan="1" colspan="1">1.7%</td><td rowspan="1" colspan="1">0.3%</td><td rowspan="1" colspan="1">6%</td></tr><tr><td rowspan="1" colspan="1">Iranian<sup><xref rid="bibr44-1076029619875520" ref-type="bibr">44</xref></sup>
</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">94%</td><td rowspan="1" colspan="1">6%</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Iranian<sup><xref rid="bibr33-1076029619875520" ref-type="bibr">33</xref></sup>
</td><td rowspan="1" colspan="1">118</td><td rowspan="1" colspan="1">80.90%</td><td rowspan="1" colspan="1">19.10%</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Qatari<sup><xref rid="bibr45-1076029619875520" ref-type="bibr">45</xref></sup>
</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">0.02%</td><td rowspan="1" colspan="1">NA</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-1076029619875520"><p>Abbreviation: NA, not applicable.</p></fn></table-wrap-foot></table-wrap><p>The frequency of <italic>CYP2C19*3</italic> allele was found to be very low, with a
maximum of 1% in Iranian population. The frequency of <italic>CYP2C19*17</italic> ranged
from 5.3% to 26.9%. Hardy-Weinberg equilibrium was tested and reported in only 9 studies.<sup><xref rid="bibr28-1076029619875520" ref-type="bibr">28</xref>,<xref rid="bibr30-1076029619875520" ref-type="bibr">30</xref><xref rid="bibr31-1076029619875520" ref-type="bibr"/>&#x02013;<xref rid="bibr32-1076029619875520" ref-type="bibr">32</xref>,<xref rid="bibr36-1076029619875520" ref-type="bibr">36</xref><xref rid="bibr37-1076029619875520" ref-type="bibr"/><xref rid="bibr38-1076029619875520" ref-type="bibr"/><xref rid="bibr39-1076029619875520" ref-type="bibr"/>&#x02013;<xref rid="bibr40-1076029619875520" ref-type="bibr">40</xref></sup>
</p></sec><sec id="section14-1076029619875520"><title>Characteristics of the Included Studies</title><p>The characteristics of the included studies are shown in <xref rid="table2-1076029619875520" ref-type="table">Table 2</xref>. The primary objective of 11 included
studies was to explore the prevalence of <italic>CYP2C19</italic> polymorphism in the MENA
region. However, the rest of the studies investigated the association between
<italic>CYP2C19</italic> polymorphism and other nongenetic factors on clopidogrel
responsiveness in MENA region. Based on the quality assessment, 6 studies were of good
quality, 2 of fair quality, and only 1 was considered of poor quality by Khalaf et al
because the objective and the population were not defined clearly. Of the 9 studies, 5
were case&#x02013;control studies while the other 4 were prospective observational studies.</p><table-wrap id="table2-1076029619875520" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Study Characteristics.</p></caption><alternatives><graphic xlink:href="10.1177_1076029619875520-table2"/><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Study (Author, Year)</th><th rowspan="1" colspan="1">Design</th><th rowspan="1" colspan="1">Quality</th><th rowspan="1" colspan="1">Participants, n</th><th rowspan="1" colspan="1">Indication</th><th rowspan="1" colspan="1">Population</th><th rowspan="1" colspan="1">Cardiovascular Risk Factors (Smoking, DM, HTN, DYS)</th><th rowspan="1" colspan="1">Clopidogrel LD</th><th rowspan="1" colspan="1">Clopidogrel MD, Duration</th><th rowspan="1" colspan="1">Follow-Up</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sen et al, 2014<sup><xref rid="bibr41-1076029619875520" ref-type="bibr">41</xref></sup>
</td><td rowspan="1" colspan="1">Observational prospective</td><td rowspan="1" colspan="1">Fair</td><td rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1">Stroke prevention</td><td rowspan="1" colspan="1">Turkish</td><td rowspan="1" colspan="1">NR</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">75 mg, 2 years</td><td rowspan="1" colspan="1">At least 1 year</td></tr><tr><td rowspan="1" colspan="1">Khalil et al, 2016<sup><xref rid="bibr36-1076029619875520" ref-type="bibr">36</xref></sup>
</td><td rowspan="1" colspan="1">Observational retrospective (case&#x02013;control)</td><td rowspan="1" colspan="1">Good</td><td rowspan="1" colspan="1">190</td><td rowspan="1" colspan="1">ACS and/or PCI</td><td rowspan="1" colspan="1">Egyptian</td><td rowspan="1" colspan="1">Smoking: 33.3% in MACE vs 23.6% in non-MACE<break/>HTN: 67.9% in MACE vs 51%
in non-MACE group<break/>DSY: NR<break/>DM: 36.9% in MACE vs 24.5% in
non-MACE</td><td rowspan="1" colspan="1">NR</td><td rowspan="1" colspan="1">75 mg, at least 3 months and maximum 12 months</td><td rowspan="1" colspan="1">3-12 months</td></tr><tr><td rowspan="1" colspan="1">Namazi et al, 2012<sup><xref rid="bibr31-1076029619875520" ref-type="bibr">31</xref></sup>
</td><td rowspan="1" colspan="1">Observational prospective (cross-sectional)</td><td rowspan="1" colspan="1">Fair</td><td rowspan="1" colspan="1">112</td><td rowspan="1" colspan="1">PCI with DES</td><td rowspan="1" colspan="1">Iranian</td><td rowspan="1" colspan="1">Smoking: 42%<break/>HTN: 51%<break/>DYS: 68%<break/>DM: 19%</td><td rowspan="1" colspan="1">600 mg</td><td rowspan="1" colspan="1">150 mg/d for 2 weeks and 75 mg for 12 months</td><td rowspan="1" colspan="1">1 month</td></tr><tr><td rowspan="1" colspan="1">Khalaf et al., 2016 <sup><xref rid="bibr35-1076029619875520" ref-type="bibr">35</xref></sup>
</td><td rowspan="1" colspan="1">Observational prospective</td><td rowspan="1" colspan="1">Poor</td><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1">ACS</td><td rowspan="1" colspan="1">Saudi</td><td rowspan="1" colspan="1">Smoking: NR<break/>HTN: 55%<break/>DYS: 50%<break/>DM: 59%</td><td rowspan="1" colspan="1">300 mg</td><td rowspan="1" colspan="1">75 mg, not documented</td><td rowspan="1" colspan="1">2-3 days</td></tr><tr><td rowspan="1" colspan="1">Saydam et al, 2017<sup><xref rid="bibr43-1076029619875520" ref-type="bibr">43</xref></sup>
</td><td rowspan="1" colspan="1">Observational prospective</td><td rowspan="1" colspan="1">Good</td><td rowspan="1" colspan="1">347</td><td rowspan="1" colspan="1">ACS and PCI</td><td rowspan="1" colspan="1">Turkish</td><td rowspan="1" colspan="1">Smoking: 25.1%<break/>HTN: 53.3%<break/>DYS: 41.8%<break/>DM: 40.3%</td><td rowspan="1" colspan="1">NR</td><td rowspan="1" colspan="1">75 mg, at least 1 week</td><td rowspan="1" colspan="1">No follow-up</td></tr><tr><td rowspan="1" colspan="1">Alhazzani et al, 2017<sup><xref rid="bibr40-1076029619875520" ref-type="bibr">40</xref></sup>
</td><td rowspan="1" colspan="1">Observational retrospective (case&#x02013;control)</td><td rowspan="1" colspan="1">Good</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">Stroke prevention</td><td rowspan="1" colspan="1">Saudi</td><td rowspan="1" colspan="1">Smoking: NR<break/>HTN: 44% in responders vs 64% in nonresponders<break/>DM:
52% in responders vs 68% in nonresponders</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">75 mg, not documented</td><td rowspan="1" colspan="1">No follow-up</td></tr><tr><td rowspan="1" colspan="1">Al-Azzam et al, 2013<sup><xref rid="bibr26-1076029619875520" ref-type="bibr">26</xref></sup>
</td><td rowspan="1" colspan="1">Observational prospective (cross-sectional)</td><td rowspan="1" colspan="1">Good</td><td rowspan="1" colspan="1">270</td><td rowspan="1" colspan="1">Cardiovascular disease</td><td rowspan="1" colspan="1">Jordanian</td><td rowspan="1" colspan="1">Smoking: 31.7%<break/>HTN: 72.5%<break/>DM: 46.3%</td><td rowspan="1" colspan="1">NR</td><td rowspan="1" colspan="1">75 mg, at least 1 week</td><td rowspan="1" colspan="1">No follow-up</td></tr><tr><td rowspan="1" colspan="1">Kirac et al, 2016<sup><xref rid="bibr27-1076029619875520" ref-type="bibr">27</xref></sup>
</td><td rowspan="1" colspan="1">Observational retrospective (case&#x02013;control)</td><td rowspan="1" colspan="1">Good</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">PCI and Stent Placement</td><td rowspan="1" colspan="1">Turkish</td><td rowspan="1" colspan="1">Smoking: 48% in control vs 46% in cases<break/>HTN: 56% in control vs 74% in
cases<break/>DYS: 48% in control vs 46% in cases<break/>DM: 28% in control vs
36% in cases</td><td rowspan="1" colspan="1">NR</td><td rowspan="1" colspan="1">75 mg, 1 year</td><td rowspan="1" colspan="1">180 days</td></tr><tr><td rowspan="1" colspan="1">Nozari et al, 2015<sup><xref rid="bibr44-1076029619875520" ref-type="bibr">44</xref></sup>
</td><td rowspan="1" colspan="1">Observational retrospective (case&#x02013;control)</td><td rowspan="1" colspan="1">Good</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">PCI</td><td rowspan="1" colspan="1">Iranian</td><td rowspan="1" colspan="1">Smoking: 20%<break/>HTN: 51.5%<break/>DYS: 62.6%<break/>DM: 26%</td><td rowspan="1" colspan="1">600 mg</td><td rowspan="1" colspan="1">75 mg, at least 1 month after</td><td rowspan="1" colspan="1">1 year</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn2-1076029619875520"><p>Abbreviations: ACS, acute coronary syndrome; DES, drug-eluting stent; DM, diabetes
mellitus; DYS, dyslipidemia; HTN, hypertension; LD, loading dose; MACE, major
cardiovascular adverse events; MD, maintenance dose; NA, not applicable; NR, not
reported; PCI, percutaneous coronary intervention.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section15-1076029619875520"><title>Clopidogrel Response Definition</title><p>The definition of clopidogrel responsiveness varied across the included studies. Among
the 9 studies, the cutoff value for HTPR was expressed using platelet aggregation in 2 studies<sup><xref rid="bibr26-1076029619875520" ref-type="bibr">26</xref>,<xref rid="bibr40-1076029619875520" ref-type="bibr">40</xref></sup> whereas it was expressed as percentage of relative platelet inhibition in 1 study.<sup><xref rid="bibr31-1076029619875520" ref-type="bibr">31</xref></sup> Two of the studies expressed the cutoff value for HTPR by the PRU.<sup><xref rid="bibr35-1076029619875520" ref-type="bibr">35</xref>,<xref rid="bibr43-1076029619875520" ref-type="bibr">43</xref></sup> The other 4 studies examined clopidogrel responsiveness by the clinical
cardiovascular outcome, mainly MACE, stroke recurrence, and stent thrombosis.<sup><xref rid="bibr27-1076029619875520" ref-type="bibr">27</xref>,<xref rid="bibr36-1076029619875520" ref-type="bibr">36</xref>,<xref rid="bibr41-1076029619875520" ref-type="bibr">41</xref>,<xref rid="bibr44-1076029619875520" ref-type="bibr">44</xref></sup>
</p></sec><sec id="section16-1076029619875520"><title>Clopidogrel Responsiveness and the LOF Variants</title><p>
<xref rid="table3-1076029619875520" ref-type="table">Table 3</xref> shows the association
between <italic>CYP2C19</italic> genetic variants and clopidogrel responsiveness in the
different populations. Of the 9 studies, 6 found an association between carriers of at
least 1 LOF allele (*2 or *3) of <italic>CYP2C19</italic> and clopidogrel responsiveness.
In 4 of these studies, the outcome assessed was the HTPR,<sup><xref rid="bibr26-1076029619875520" ref-type="bibr">26</xref>,<xref rid="bibr27-1076029619875520" ref-type="bibr">27</xref>,<xref rid="bibr40-1076029619875520" ref-type="bibr">40</xref>,<xref rid="bibr43-1076029619875520" ref-type="bibr">43</xref></sup> while clinical cardiovascular events were the measured outcomes in the other 2 studies.<sup><xref rid="bibr36-1076029619875520" ref-type="bibr">36</xref>,<xref rid="bibr41-1076029619875520" ref-type="bibr">41</xref></sup>
</p><table-wrap id="table3-1076029619875520" orientation="portrait" position="float"><label>Table 3.</label><caption><p>
<italic>CYP2C19</italic> Genetic Variants and Clopidogrel Responsiveness.<sup>a</sup>
</p></caption><alternatives><graphic xlink:href="10.1177_1076029619875520-table3"/><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Population</th><th rowspan="1" colspan="1">Genetic Polymorphism Studied</th><th rowspan="1" colspan="1">Outcomes Reported</th><th rowspan="1" colspan="1">
<italic>CYP2C19</italic> Polymorphism Association Results</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Turkish<sup><xref rid="bibr41-1076029619875520" ref-type="bibr">41</xref></sup>
</td><td rowspan="1" colspan="1">
<italic>CYP2C19</italic> (*2 and *3)</td><td rowspan="1" colspan="1">Recurrent Stroke</td><td rowspan="1" colspan="1">In *2 carriers, OR = 13.23; 95% CI, 6.45-27.11 for recurrent stroke.</td></tr><tr><td rowspan="1" colspan="1">Egyptian<sup><xref rid="bibr36-1076029619875520" ref-type="bibr">36</xref></sup>
</td><td rowspan="1" colspan="1">
<italic>CYP2C19</italic> (*2, *3, *6, *8, *10, and *17)</td><td rowspan="1" colspan="1">MACE</td><td rowspan="1" colspan="1">In LOF alleles carriers, OR = 2.52; 95% CI, 1.23&#x02013;5.15.</td></tr><tr><td rowspan="1" colspan="1">Iranian<sup><xref rid="bibr31-1076029619875520" ref-type="bibr">31</xref></sup>
</td><td rowspan="1" colspan="1">
<italic>CYP2C19</italic> (*2 and *3)</td><td rowspan="1" colspan="1">Relative platelet inhibition</td><td rowspan="1" colspan="1">No significant associations between clopidogrel responsiveness and
<italic>CYP2C19</italic> polymorphism, <italic>P</italic> &#x0003e; .05.</td></tr><tr><td rowspan="1" colspan="1">Saudi<sup><xref rid="bibr35-1076029619875520" ref-type="bibr">35</xref></sup>
</td><td rowspan="1" colspan="1">
<italic>CYP2C19</italic> (*2, and *3)</td><td rowspan="1" colspan="1">PRU</td><td rowspan="1" colspan="1">No significant difference in PRU, <italic>P</italic> = .349.</td></tr><tr><td rowspan="1" colspan="1">Turkish<sup><xref rid="bibr43-1076029619875520" ref-type="bibr">43</xref></sup>
</td><td rowspan="1" colspan="1">
<italic>CYP2C19</italic> (*2, *3, *4, *7, *8, and *17)</td><td rowspan="1" colspan="1">PRU</td><td rowspan="1" colspan="1">In *2 carriers, OR = 2.92; 95% CI, 1.91-4.46 for high PRU.<break/>PRU values
of <italic>CYP2C19</italic>*1/*17 were lower (<italic>P</italic> = .029) vs
*1/*1.</td></tr><tr><td rowspan="1" colspan="1">Saudi<sup><xref rid="bibr40-1076029619875520" ref-type="bibr">40</xref></sup>
</td><td rowspan="1" colspan="1">
<italic>CYP2C19</italic> (*2 and *3)</td><td rowspan="1" colspan="1">Platelet aggregation</td><td rowspan="1" colspan="1">In *2 carriers, OR = 5.52; 95% CI, 2.42-12.83 for high platelet
aggregation.<break/>In *3 carriers, OR = 3.45; 95% CI, 1.57-7.70 high platelet
aggregation.</td></tr><tr><td rowspan="1" colspan="1">Jordanian<sup><xref rid="bibr26-1076029619875520" ref-type="bibr">26</xref></sup>
</td><td rowspan="1" colspan="1">
<italic>CYP2C19</italic>*2</td><td rowspan="1" colspan="1">Platelet aggregation</td><td rowspan="1" colspan="1">Patients with*2 allele were more resistant to clopidogrel than *1 allele
(<italic>P</italic> &#x0003c; .05).<break/>In *2 carriers, OR = 1.3; 95% CI,
0.6-2.6.<break/>In *2/*2, OR = 4.6; 95% CI, 1.4-14.2.</td></tr><tr><td rowspan="1" colspan="1">Turkish<sup><xref rid="bibr27-1076029619875520" ref-type="bibr">27</xref></sup>
</td><td rowspan="1" colspan="1">
<italic>CYP2C19</italic> (*2, *3, *4, *5, and *17)</td><td rowspan="1" colspan="1">Stent thrombosis</td><td rowspan="1" colspan="1">There were more *2 allele carriers in clopidogrel-resistant patients,
<italic>P</italic> = .000005.<break/>*17 allele may prevent ST,
<italic>P</italic> = .042.</td></tr><tr><td rowspan="1" colspan="1">Iranian<sup><xref rid="bibr44-1076029619875520" ref-type="bibr">44</xref></sup>
</td><td rowspan="1" colspan="1">
<italic>CYP2C19</italic>*2</td><td rowspan="1" colspan="1">Stent thrombosis</td><td rowspan="1" colspan="1">No significant associations between clopidogrel responsiveness and
<italic>CYP2C19</italic> polymorphism. In *2 carriers, OR = 2.5; 95% CI,
0.49-12.89.</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn3-1076029619875520"><p>Abbreviations: CI, confidence interval; LOF, loss of function; MACE, major
cardiovascular adverse events; OR, odds ratio; PRU, platelet reactivity unit; ST,
stent thrombosis.</p></fn><fn id="table-fn4-1076029619875520"><p>
<sup>a</sup>&#x0200a;LOF allele carriers were *1/*2, *1/*3, *2/*3, and *2/*17.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section17-1076029619875520"><title>Clopidogrel Response Across Different Indications</title><p>Among the 9 included studies, 2 had evaluated the association between having at least 1
LOF allele (*2 or *3) of <italic>CYP2C19</italic> and clopidogrel responsiveness in stroke
prevention. The remaining 7 studies included patients who underwent PCI.<sup><xref rid="bibr26-1076029619875520" ref-type="bibr">26</xref>,<xref rid="bibr27-1076029619875520" ref-type="bibr">27</xref>,<xref rid="bibr31-1076029619875520" ref-type="bibr">31</xref>,<xref rid="bibr35-1076029619875520" ref-type="bibr">35</xref>,<xref rid="bibr36-1076029619875520" ref-type="bibr">36</xref>,<xref rid="bibr43-1076029619875520" ref-type="bibr">43</xref>,<xref rid="bibr44-1076029619875520" ref-type="bibr">44</xref></sup> Sen et al evaluated the effect of <italic>CYP2C19</italic> polymorphism on the
clinical outcomes of patients who began clopidogrel therapy after acute ischemic
cerebrovascular disease.<sup><xref rid="bibr41-1076029619875520" ref-type="bibr">41</xref></sup> However, the other study used platelet aggregation as a surrogate marker to study
the effect of <italic>CYP2C19</italic> polymorphisms on clopidogrel response in patients
with acute ischemic stroke.<sup><xref rid="bibr40-1076029619875520" ref-type="bibr">40</xref></sup>
</p><p>These studies found that carrying at least 1 LOF allele (*2 or *3) of
<italic>CYP2C19</italic> is associated with recurrent stroke linked to insufficient
response to clopidogrel.<sup><xref rid="bibr40-1076029619875520" ref-type="bibr">40</xref>,<xref rid="bibr41-1076029619875520" ref-type="bibr">41</xref></sup> Regarding clopidogrel responsiveness in patients who underwent PCI, 4 studies
showed a significant association between LOF alleles and clopidogrel resistance.<sup><xref rid="bibr26-1076029619875520" ref-type="bibr">26</xref>,<xref rid="bibr27-1076029619875520" ref-type="bibr">27</xref>,<xref rid="bibr36-1076029619875520" ref-type="bibr">36</xref>,<xref rid="bibr43-1076029619875520" ref-type="bibr">43</xref></sup> On the other hand, 3 studies revealed that carrying at least 1 LOF is not a
contributing factor in clopidogrel resistance in patients who were treated with
clopidogrel after PCI.<sup><xref rid="bibr31-1076029619875520" ref-type="bibr">31</xref>,<xref rid="bibr35-1076029619875520" ref-type="bibr">35</xref>,<xref rid="bibr44-1076029619875520" ref-type="bibr">44</xref></sup>
</p></sec><sec id="section18-1076029619875520"><title>Clopidogrel Responsiveness and the Gain-of-Function Variant</title><p>Of the 9 studies, 3 examined the effect of <italic>CYP2C19*17</italic> on clopidogrel
responsiveness. One study found that PRU values in <italic>CYP2C19*1/*17</italic> carriers
were significantly lower than in wild-type patients (<italic>P</italic> = .029).<sup><xref rid="bibr43-1076029619875520" ref-type="bibr">43</xref></sup> Another study showed that <italic>CYP2C19*17</italic> mutation may have protective
effect by preventing stent thrombosis.<sup><xref rid="bibr27-1076029619875520" ref-type="bibr">27</xref></sup>
</p></sec><sec id="section19-1076029619875520"><title>Clopidogrel Responsiveness and Nongenetic Factors</title><p>
<xref rid="table4-1076029619875520" ref-type="table">Table 4</xref> represents the
association between the nongenetic factors and clopidogrel responsiveness. Only 4 studies
examined the effect of nongenetic factors on clopidogrel response. Three of them showed a
significant association between the nongenetic factors and clopidogrel response.<sup><xref rid="bibr26-1076029619875520" ref-type="bibr">26</xref>,<xref rid="bibr35-1076029619875520" ref-type="bibr">35</xref>,<xref rid="bibr36-1076029619875520" ref-type="bibr">36</xref></sup> Two studies showed that females are at increased risk of clopidogrel resistance
when compared to males.<sup><xref rid="bibr26-1076029619875520" ref-type="bibr">26</xref>,<xref rid="bibr35-1076029619875520" ref-type="bibr">35</xref></sup> In one of the former 2 studies, use of calcium channel blockers (CCBs) was also
associated with clopidogrel resistance.<sup><xref rid="bibr26-1076029619875520" ref-type="bibr">26</xref></sup> The third study showed that age and body mass index (BMI) were significantly
associated with the incidence of MACE in patients taking clopidogrel.<sup><xref rid="bibr36-1076029619875520" ref-type="bibr">36</xref></sup>
</p><table-wrap id="table4-1076029619875520" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Nongenetic Factors and Clopidogrel Responsiveness.</p></caption><alternatives><graphic xlink:href="10.1177_1076029619875520-table4"/><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Population</th><th rowspan="1" colspan="1">Outcomes Reported</th><th rowspan="1" colspan="1">Nongenetic Factors Studied</th><th rowspan="1" colspan="1">Nongenetic Factors Association Results</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Egyptian<sup><xref rid="bibr36-1076029619875520" ref-type="bibr">36</xref></sup>
</td><td rowspan="1" colspan="1">MACE</td><td rowspan="1" colspan="1">Age, BMI, smoking</td><td rowspan="1" colspan="1">A year older increases the odds of MACE by 3%, OR = 1.03; 95% CI,
1.003-1.07.<break/>Every 1-unit increase in BMI increases the odds of MACE by
8%, OR = 1.08; 95% CI, 1.004-1.181.</td></tr><tr><td rowspan="1" colspan="1">Iranian<sup><xref rid="bibr31-1076029619875520" ref-type="bibr">31</xref></sup>
</td><td rowspan="1" colspan="1">Relative platelet inhibition</td><td rowspan="1" colspan="1">Age, BMI, sex</td><td rowspan="1" colspan="1">No significant associations between nongenetic factors and clopidogrel
responsiveness (<italic>P</italic> &#x0003e; .05).</td></tr><tr><td rowspan="1" colspan="1">Saudi<sup><xref rid="bibr35-1076029619875520" ref-type="bibr">35</xref></sup>
</td><td rowspan="1" colspan="1">PRU</td><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1">The PRU of the female patients was significantly higher than males (255.6 &#x000b1;
68.8 and 177.7 &#x000b1; 66.6, <italic>P</italic> = .000, respectively).</td></tr><tr><td rowspan="1" colspan="1">Jordanian<sup><xref rid="bibr26-1076029619875520" ref-type="bibr">26</xref></sup>
</td><td rowspan="1" colspan="1">Platelet aggregation</td><td rowspan="1" colspan="1">Age, obesity, DM, HTN, smoking, and concomitant medication use</td><td rowspan="1" colspan="1">Females have higher risk of clopidogrel resistance. OR = 3.7; 95% CI, 1.8-7.7,
<italic>P</italic> &#x0003c; .001.<break/>Use of CCBs is associated with higher
risk of clopidogrel resistance by 3.3 times, <italic>P</italic> =
.006.<break/>Elevated HDL level reduces the OR of clopidogrel resistance. OR =
0.97; 95% CI, 0.95-99, <italic>P</italic> &#x0003c; .020.</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn5-1076029619875520"><p>Abbreviations: BMI, body mass index; CCBs, calcium channel blockers; CI, confidence
interval; DM, diabetes mellitus; HDL, high-density lipoprotein; HTN, hypertension;
MACE, major cardiovascular adverse events; OR, odds ratio.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="section20-1076029619875520"><title>Discussion</title><p>This systematic review was conducted to explore the prevalence of <italic>CYP2C19</italic>
variants in MENA region and the different genetic and nongenetic factors associated with
clopidogrel responsiveness.</p><p>Eleven of the included studies identified only the prevalence of <italic>CYP2C19</italic>
polymorphism in the MENA region. Similar to Caucasians, MAF of <italic>CYP2C19*2</italic>
was much higher than <italic>CYP2C19*3</italic> and it ranged from 1.7% to 35%.<sup><xref rid="bibr11-1076029619875520" ref-type="bibr">11</xref></sup> There were some inconsistencies in the reported MAF of <italic>CYP2C19*2</italic> in
Iranian populations and these variations maybe due to the differences in the studied sample
size and the geographical distribution across the studied populations. The
<italic>CYP2C19*3</italic> frequency was very low with a maximum of 1% in the Iranian
population, which was similar to other racial groups (Caucasians and Africans).<sup><xref rid="bibr11-1076029619875520" ref-type="bibr">11</xref></sup> In this systematic review, the frequency of <italic>CYP2C19*17</italic> ranged from
5.3% to 26.9%, which was marginally higher than the average multiethnic allele frequencies (3%-21%).<sup><xref rid="bibr11-1076029619875520" ref-type="bibr">11</xref></sup>
</p><p>The other studies in this review investigated the association between
<italic>CYP2C19</italic> polymorphism along with nongenetic factors on clopidogrel
responsiveness in the MENA region. Of the 9 studies, 6 found an association between carriers
of at least 1 LOF allele (*2 or *3) of <italic>CYP2C19</italic> and clopidogrel
responsiveness. Numerous studies conducted outside the MENA region have demonstrated similar findings.<sup><xref rid="bibr46-1076029619875520" ref-type="bibr">46</xref></sup> Several factors can explain the inconsistency of results among the reviewed studies,
including the small sample size (lack of power), study design, variation in clopidogrel
responsiveness definition, the studied <italic>CYP2C19</italic> variants, and the follow-up
duration.</p><p>Among the 9 studies, clopidogrel resistance was measured based on a surrogate marker in 5 studies.<sup><xref rid="bibr26-1076029619875520" ref-type="bibr">26</xref>,<xref rid="bibr31-1076029619875520" ref-type="bibr">31</xref>,<xref rid="bibr35-1076029619875520" ref-type="bibr">35</xref>,<xref rid="bibr40-1076029619875520" ref-type="bibr">40</xref>,<xref rid="bibr43-1076029619875520" ref-type="bibr">43</xref></sup> Two of these studies showed that carrying at least 1 LOF allele is not associated
with clopidogrel resistance based on relative platelet inhibition or PRU measurement.<sup><xref rid="bibr31-1076029619875520" ref-type="bibr">31</xref>,<xref rid="bibr35-1076029619875520" ref-type="bibr">35</xref></sup> On the other hand, 4 studies examined clopidogrel responsiveness by the clinical
cardiovascular outcome, mainly MACE, stroke recurrence, and stent thrombosis.<sup><xref rid="bibr36-1076029619875520" ref-type="bibr">36</xref>,<xref rid="bibr41-1076029619875520" ref-type="bibr">41</xref>,<xref rid="bibr44-1076029619875520" ref-type="bibr">44</xref></sup> Of these 4 studies, 3 showed an association between LOF allele and MACE, stent
thrombosis, or stroke recurrence.<sup><xref rid="bibr27-1076029619875520" ref-type="bibr">27</xref>,<xref rid="bibr36-1076029619875520" ref-type="bibr">36</xref>,<xref rid="bibr41-1076029619875520" ref-type="bibr">41</xref></sup> In the remaining study, genetic variants were not associated with treatment failure,
which was measured using stent thrombosis as an end point.<sup><xref rid="bibr44-1076029619875520" ref-type="bibr">44</xref></sup> This insignificant result may possibly be due to the low prevalence of the
<italic>CYP2C19*2</italic> allele in the studied population, the small sample size, and,
consequently, low statistical power.</p><p>Regarding the nongenetic factors, in this systematic review, females were at increased risk
of clopidogrel resistance. Additionally, older age, high BMI, and use of CCBs were
associated with the incidence of MACE in clopidogrel-treated patients. In previous studies,
it was reported that females had poorer clopidogrel response.<sup><xref rid="bibr47-1076029619875520" ref-type="bibr">47</xref>,<xref rid="bibr48-1076029619875520" ref-type="bibr">48</xref></sup> In contrast, a meta-analysis found that there was no significant difference in
clopidogrel response between males and females.<sup><xref rid="bibr49-1076029619875520" ref-type="bibr">49</xref></sup> Results on the concomitant CCBs use and poor clopidogrel response were also
replicated in previous studies.<sup><xref rid="bibr50-1076029619875520" ref-type="bibr">50</xref>,<xref rid="bibr51-1076029619875520" ref-type="bibr">51</xref></sup> This interaction could be due to the inhibition of <italic>CYP3A4</italic> by CCBs,<sup><xref rid="bibr52-1076029619875520" ref-type="bibr">52</xref></sup> which may result in lower concentration of clopidogrel active metabolite.<sup><xref rid="bibr50-1076029619875520" ref-type="bibr">50</xref>,<xref rid="bibr51-1076029619875520" ref-type="bibr">51</xref></sup>
</p><p>One may argue that studying clopidogrel pharmacogenetics is not that important, since we
can use the more potent P2Y12 blockers (prasugrel and ticagrelor) that are also less likely
to be associated with interpatient variability.<sup><xref rid="bibr53-1076029619875520" ref-type="bibr">53</xref></sup> However, studies have shown that clopidogrel is still the most commonly prescribed antiplatelet.<sup><xref rid="bibr54-1076029619875520" ref-type="bibr">54</xref></sup> This may be due to its reasonable price that may enhance patient adherence.
Additionally, clopidogrel is associated with lower bleeding risk compared to prasugrel and ticagrelor.<sup><xref rid="bibr55-1076029619875520" ref-type="bibr">55</xref>,<xref rid="bibr56-1076029619875520" ref-type="bibr">56</xref></sup>
</p><p>To overcome clopidogrel treatment failure, a study by Mega et al examined the effect of
increasing clopidogrel dose in patients with <italic>CYP2C19</italic> polymorphism and found
that doses up to 225 mg daily in heterozygous patients (*1/*2) would overcome the increase
in platelet reactivity without any noticed side effects.<sup><xref rid="bibr57-1076029619875520" ref-type="bibr">57</xref></sup> Hence, <italic>CYP2C19*2</italic> genetic testing might significantly improve the
cardiovascular outcomes in patients treated with clopidogrel. In the same line, an ongoing
prospective, randomized trial&#x02014;tailored antiplatelet therapy following PCI (TAILOR-PCI)&#x02014;is
aiming to determine whether the best antiplatelet therapy can be identified based on genetic
testing for patients undergoing coronary stent placement (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> Identifier:
NCT01742117). In this study, patient will be randomized to either conventional therapy arm
(clopidogrel 75 mg once daily without prospective genotyping guidance) or to the prospective
<italic>CYP2C19</italic> genotype-based arm (ticagrelor 90 mg twice daily in
<italic>CYP2C19 *2</italic> or <italic>*3</italic> carriers, clopidogrel 75 mg once daily
in non-*2 or -*3 <italic>CYP2C19</italic> patients).</p><p>Our systematic review has some limitations. First of all, important SNPs like
<italic>CYP2C19*3</italic> and <italic>CYP2C19*17</italic> were explored in a very limited
number of the reviewed studies. Thus, it was difficult to come up with a conclusion
regarding the effect of these variants on clopidogrel responsiveness in MENA populations.
Additionally, the effect of <italic>CYP2C19</italic> genetic polymorphism was not studied in
many populations of the MENA. Third, the bleeding outcome was not assessed in any of the
studies as a clinical outcome. Lastly, some of the included studies had small sample sizes.
Nevertheless, this is the first systematic review that assessed the effect of genetic and
non-genetic factors in MENA region.</p></sec><sec sec-type="conclusions" id="section21-1076029619875520"><title>Conclusion</title><p>Association between the <italic>CYP2C19*2</italic> allele as well as nongenetic factors and
clopidogrel resistance has been replicated in MENA populations. Future studies should focus
on having larger sample sizes to detect other minor variant alleles and their effect on
bleeding and cardiovascular outcomes in clopidogrel users. Future studies in the region
should have longer follow-up duration and consistent clopidogrel resistance outcome
definitions, either in term of HTPR or the clinical cardiovascular outcomes. Finally,
studies should evaluate the cost-utility of genotype-guided therapy, compared with standard
clopidogrel dosing or the other novel antiplatelet agents without genotyping.</p></sec><sec sec-type="supplementary-material" id="section23-1076029619875520" specific-use="figshare"><title>Supplemental Material</title><supplementary-material content-type="local-data" id="suppl1-1076029619875520"><caption><title>Supplemental Material, PRISMA_2009_checklist - The Effect of CYP2C19 and Nongenetic
Factors on Clopidogrel Responsiveness in the MENA Region: A Systematic Review</title></caption><media xlink:href="PRISMA_2009_checklist.pdf"><caption><p>Click here for additional data file.</p></caption></media><p>Supplemental Material, PRISMA_2009_checklist for The Effect of CYP2C19 and Nongenetic
Factors on Clopidogrel Responsiveness in the MENA Region: A Systematic Review by Zainab
Ali and Hazem Elewa in Clinical and Applied Thrombosis/Hemostasis</p></supplementary-material></sec></body><back><fn-group><fn fn-type="other" id="fn1-1076029619875520"><p><bold>Authors' Note:</bold> ZA and HE contributed to conceptualization, data collection, formal analysis, funding
acquisition, investigation, methodology, project administration, and validation. HE
supervised the manuscript.</p></fn><fn fn-type="other" id="fn2-1076029619875520"><p><bold>Data Availability:</bold> All relevant data are freely available and are within the paper.</p></fn><fn fn-type="COI-statement" id="fn3-1076029619875520"><p><bold>Declaration of Conflicting Interests:</bold> The author(s) declared no potential conflicts of interest with respect to the research,
authorship, and/or publication of this article.</p></fn><fn fn-type="financial-disclosure" id="fn4-1076029619875520"><p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the research,
authorship, and/or publication of this article: This research was funded by Hamad Medical
Corporation, Doha, Qatar (grant number - IRGC-02-NI-052). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the
manuscript.</p></fn><fn fn-type="other" id="fn6-1076029619875520"><p><bold>ORCID iD:</bold> Zainab Ali <inline-graphic xlink:href="10.1177_1076029619875520-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-7667-2546">https://orcid.org/0000-0002-7667-2546</ext-link>
</p></fn><fn fn-type="supplementary-material" id="fn5-1076029619875520"><p><bold>Supplemental Material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1076029619875520"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kitzmiller</surname><given-names>JP</given-names></name><name><surname>Groen</surname><given-names>DK</given-names></name><name><surname>Phelps</surname><given-names>MA</given-names></name><name><surname>Sadee</surname><given-names>W</given-names></name></person-group>
<article-title>Pharmacogenomic testing: relevance in medical practice:
why drugs work in some patients but not in others</article-title>. <source>Cleve Clin J
Med</source>.
<year>2011</year>;<volume>78</volume>(<issue>4</issue>):<fpage>243</fpage>&#x02013;<lpage>257</lpage>.
<comment>doi:10.3949/ccjm.78a.10145</comment>.<pub-id pub-id-type="pmid">21460130</pub-id></mixed-citation></ref><ref id="bibr2-1076029619875520"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adams</surname><given-names>RJ</given-names></name><name><surname>Albers</surname><given-names>G</given-names></name><name><surname>Alberts</surname><given-names>MJ</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Update to the AHA/ASA recommendations for the prevention of stroke in
patients with stroke and transient ischemic attack</article-title>.
<source>Stroke</source>.
<year>2008</year>;<volume>39</volume>(<issue>5</issue>):<fpage>1647</fpage>&#x02013;<lpage>1652</lpage>.
<comment>doi:10.1161/STROKEAHA.107.189063</comment>.<pub-id pub-id-type="pmid">18322260</pub-id></mixed-citation></ref><ref id="bibr3-1076029619875520"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steinhubl</surname><given-names>SR</given-names></name><name><surname>Berger</surname><given-names>PB</given-names></name><name><surname>Mann</surname><given-names>JT</given-names><suffix>3 rd</suffix></name></person-group>, <etal>et al.</etal>
<article-title>Early and sustained dual oral antiplatelet therapy following percutaneous
coronary intervention: a randomized controlled trial</article-title>.
<source>JAMA</source>.
<year>2002</year>;<volume>288</volume>(<issue>19</issue>):<fpage>2411</fpage>&#x02013;<lpage>2420</lpage>.<pub-id pub-id-type="pmid">12435254</pub-id></mixed-citation></ref><ref id="bibr4-1076029619875520"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JA</given-names></name><name><surname>Cavallari</surname><given-names>LH</given-names></name></person-group>
<article-title>Pharmacogenetics and cardiovascular disease &#x02013; implications
for personalized medicine</article-title>. <source>Pharmacol Rev</source>.
<year>2013</year>;<volume>65</volume>(<issue>3</issue>):<fpage>987</fpage>&#x02013;<lpage>1009</lpage>.
<comment>doi:10.1124/pr.112.007252</comment>.<pub-id pub-id-type="pmid">23686351</pub-id></mixed-citation></ref><ref id="bibr5-1076029619875520"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>TK</given-names></name><name><surname>Lam</surname><given-names>YY</given-names></name><name><surname>Tan</surname><given-names>VP</given-names></name><name><surname>Yan</surname><given-names>BP</given-names></name></person-group>
<article-title>Variability in response to clopidogrel: how important are
pharmacogenetics and drug interactions?</article-title>
<source>Br J Clin Pharmacol</source>.
<year>2011</year>;<volume>72</volume>(<issue>4</issue>):<fpage>697</fpage>&#x02013;<lpage>706</lpage>.
<comment>doi:10.1111/j.1365-2125.2011.03949.x</comment>.<pub-id pub-id-type="pmid">21352268</pub-id></mixed-citation></ref><ref id="bibr6-1076029619875520"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siller-Matula</surname><given-names>JM</given-names></name><name><surname>Trenk</surname><given-names>D</given-names></name><name><surname>Schror</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal>
<article-title>How to improve the concept of individualised antiplatelet therapy with
P2Y12 receptor inhibitors &#x02013; is an algorithm the answer?</article-title>
<source>Thromb Haemost</source>.
<year>2015</year>;<volume>113</volume>(<issue>1</issue>):<fpage>37</fpage>&#x02013;<lpage>52</lpage>.
<comment>doi:10.1160/TH14-03-0238</comment>.<pub-id pub-id-type="pmid">25231675</pub-id></mixed-citation></ref><ref id="bibr7-1076029619875520"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Camilleri</surname><given-names>E</given-names></name><name><surname>Jacquin</surname><given-names>L</given-names></name><name><surname>Paganelli</surname><given-names>F</given-names></name><name><surname>Bonello</surname><given-names>L</given-names></name></person-group>
<article-title>Personalized antiplatelet therapy: review of the latest
clinical evidence</article-title>. <source>Curr Cardiol Rep</source>.
<year>2011</year>;<volume>13</volume>(<issue>4</issue>):<fpage>296</fpage>&#x02013;<lpage>302</lpage>.
<comment>doi:10.1007/s11886-011-0194-1</comment>.<pub-id pub-id-type="pmid">21594586</pub-id></mixed-citation></ref><ref id="bibr8-1076029619875520"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Angiolillo</surname><given-names>DJ</given-names></name><name><surname>Fernandez-Ortiz</surname><given-names>A</given-names></name><name><surname>Bernardo</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Variability in individual responsiveness to clopidogrel: clinical
implications, management, and future perspectives</article-title>. <source>J Am Coll
Cardiol</source>.
<year>2007</year>;<volume>49</volume>(<issue>14</issue>):<fpage>1505</fpage>&#x02013;<lpage>1516</lpage>.
<comment>doi:10.1016/j.jacc.2006.11.044</comment>.<pub-id pub-id-type="pmid">17418288</pub-id></mixed-citation></ref><ref id="bibr9-1076029619875520"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sangkuhl</surname><given-names>K</given-names></name><name><surname>Klein</surname><given-names>TE</given-names></name><name><surname>Altman</surname><given-names>RB</given-names></name></person-group>
<article-title>Clopidogrel pathway</article-title>. <source>Pharmacogenet
Genomics</source>.
<year>2010</year>;<volume>20</volume>(<issue>7</issue>):<fpage>463</fpage>&#x02013;<lpage>465</lpage>.
<comment>doi:10.1097/FPC.0b013e3283385420</comment>.<pub-id pub-id-type="pmid">20440227</pub-id></mixed-citation></ref><ref id="bibr10-1076029619875520"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kazui</surname><given-names>M</given-names></name><name><surname>Nishiya</surname><given-names>Y</given-names></name><name><surname>Ishizuka</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Identification of the human cytochrome P450 enzymes involved in the two
oxidative steps in the bioactivation of clopidogrel to its pharmacologically active
metabolite</article-title>. <source>Drug Metab Dispos</source>.
<year>2010</year>;<volume>38</volume>(<issue>1</issue>):<fpage>92</fpage>&#x02013;<lpage>99</lpage>.
<comment>doi:10.1124/dmd.109.029132</comment>.<pub-id pub-id-type="pmid">19812348</pub-id></mixed-citation></ref><ref id="bibr11-1076029619875520"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scott</surname><given-names>SA</given-names></name><name><surname>Sangkuhl</surname><given-names>K</given-names></name><name><surname>Stein</surname><given-names>CM</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Clinical pharmacogenetics implementation consortium guidelines for CYP2C19
genotype and clopidogrel therapy: 2013 update</article-title>. <source>Clin Pharmacol
Ther</source>.
<year>2013</year>;<volume>94</volume>(<issue>3</issue>):<fpage>317</fpage>&#x02013;<lpage>323</lpage>.
<comment>doi:10.1038/clpt.2013.105</comment>.<pub-id pub-id-type="pmid">23698643</pub-id></mixed-citation></ref><ref id="bibr12-1076029619875520"><label>12</label><mixed-citation publication-type="other">
<collab collab-type="author">FDA drug safety communication: reduced effectiveness of
plavix (clopidogrel) in patients who are poor metabolizers of the drug</collab>.
<year>2010</year>
<ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-reduced-effectiveness-plavix-clopidogrel-patients-who-are-poor">https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-reduced-effectiveness-plavix-clopidogrel-patients-who-are-poor</ext-link>.
<comment>Accessed August 31, 2019</comment>.</mixed-citation></ref><ref id="bibr13-1076029619875520"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Geisler</surname><given-names>T</given-names></name><name><surname>Schaeffeler</surname><given-names>E</given-names></name><name><surname>Dippon</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal>
<article-title>CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel
loading dose after coronary stent implantation</article-title>.
<source>Pharmacogenomics</source>.
<year>2008</year>;<volume>9</volume>(<issue>9</issue>):<fpage>1251</fpage>&#x02013;<lpage>1259</lpage>.
<comment>doi:10.2217/14622416.9.9.1251</comment>.<pub-id pub-id-type="pmid">18781853</pub-id></mixed-citation></ref><ref id="bibr14-1076029619875520"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mega</surname><given-names>JL</given-names></name><name><surname>Simon</surname><given-names>T</given-names></name><name><surname>Collet</surname><given-names>JP</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes
among patients treated with clopidogrel predominantly for PCI: a
meta-analysis</article-title>. <source>JAMA</source>.
<year>2010</year>;<volume>304</volume>(<issue>16</issue>):<fpage>1821</fpage>&#x02013;<lpage>1830</lpage>.
<comment>doi:10.1001/jama.2010.1543</comment>.<pub-id pub-id-type="pmid">20978260</pub-id></mixed-citation></ref><ref id="bibr15-1076029619875520"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JA</given-names></name><name><surname>Roden</surname><given-names>DM</given-names></name><name><surname>Lesko</surname><given-names>LJ</given-names></name><name><surname>Ashley</surname><given-names>E</given-names></name><name><surname>Klein</surname><given-names>TE</given-names></name><name><surname>Shuldiner</surname><given-names>AR</given-names></name></person-group>
<article-title>Clopidogrel: a case for indication-specific
pharmacogenetics</article-title>. <source>Clin Pharmacol Ther</source>.
<year>2012</year>;<volume>91</volume>(<issue>5</issue>):<fpage>774</fpage>&#x02013;<lpage>776</lpage>.
<comment>doi:10.1038/clpt.2012.21</comment>.<pub-id pub-id-type="pmid">22513313</pub-id></mixed-citation></ref><ref id="bibr16-1076029619875520"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>HL</given-names></name><name><surname>Hu</surname><given-names>YF</given-names></name><name><surname>Xie</surname><given-names>HG</given-names></name></person-group>
<article-title>The gain-of-function variant allele CYP2C19*17: a
double-edged sword between thrombosis and bleeding in clopidogrel-treated
patients</article-title>. <source>J Thromb Haemost</source>.
<year>2012</year>;<volume>10</volume>(<issue>2</issue>):<fpage>199</fpage>&#x02013;<lpage>206</lpage>.
<comment>doi:10.1111/j.1538-7836.2011.04570.x</comment>.<pub-id pub-id-type="pmid">22123356</pub-id></mixed-citation></ref><ref id="bibr17-1076029619875520"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kip</surname><given-names>KE</given-names></name><name><surname>Hollabaugh</surname><given-names>K</given-names></name><name><surname>Marroquin</surname><given-names>OC</given-names></name><name><surname>Williams</surname><given-names>DO</given-names></name></person-group>
<article-title>The problem with composite end points in cardiovascular
studies: the story of major adverse cardiac events and percutaneous coronary
intervention</article-title>. <source>J Am Coll Cardiol</source>.
<year>2008</year>;<volume>51</volume>(<issue>7</issue>):<fpage>701</fpage>&#x02013;<lpage>707</lpage>.
<comment>doi:10.1016/j.jacc.2007.10.034</comment>.<pub-id pub-id-type="pmid">18279733</pub-id></mixed-citation></ref><ref id="bibr18-1076029619875520"><label>18</label><mixed-citation publication-type="web">
<collab collab-type="author">Health NIo</collab>. <article-title>Quality assessment tool
for observatioanl cohort and cross-sectional studies</article-title>. <year>2014</year>
<ext-link ext-link-type="uri" xlink:href="https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort">https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort</ext-link>.
<comment>Accessed August 31, 2019</comment>.</mixed-citation></ref><ref id="bibr19-1076029619875520"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cresci</surname><given-names>S</given-names></name><name><surname>Depta</surname><given-names>JP</given-names></name><name><surname>Lenzini</surname><given-names>PA</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Cytochrome p450 gene variants, race, and mortality among
clopidogrel-treated patients after acute myocardial infarction</article-title>.
<source>Circ Cardiovasc Genet</source>.
<year>2014</year>;<volume>7</volume>(<issue>3</issue>):<fpage>277</fpage>&#x02013;<lpage>286</lpage>.
<comment>doi:10.1161/CIRCGENETICS.113.000303</comment>.<pub-id pub-id-type="pmid">24762860</pub-id></mixed-citation></ref><ref id="bibr20-1076029619875520"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Viviani Anselmi</surname><given-names>C</given-names></name><name><surname>Briguori</surname><given-names>C</given-names></name><name><surname>Roncarati</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Routine assessment of on-clopidogrel platelet reactivity and gene
polymorphisms in predicting clinical outcome following drug-eluting stent implantation
in patients with stable coronary artery disease</article-title>. <source>JACC Cardiovasc
Interv</source>.
<year>2013</year>;<volume>6</volume>(<issue>11</issue>):<fpage>1166</fpage>&#x02013;<lpage>1175</lpage>.
<comment>doi:10.1016/j.jcin.2013.06.010</comment>.<pub-id pub-id-type="pmid">24262617</pub-id></mixed-citation></ref><ref id="bibr21-1076029619875520"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choi</surname><given-names>IJ</given-names></name><name><surname>Koh</surname><given-names>YS</given-names></name><name><surname>Park</surname><given-names>MW</given-names></name></person-group>, <etal>et al.</etal>
<article-title>CYP2C19 loss-of-function alleles are not associated with clinical outcome
of clopidogrel therapy in patients treated with newer-generation drug-eluting
stents</article-title>. <source>Medicine (Baltimore)</source>.
<year>2016</year>;<volume>95</volume>(<issue>26</issue>):<fpage>e4049</fpage>
<comment>doi:10.1097/MD.0000000000004049</comment>.<pub-id pub-id-type="pmid">27368038</pub-id></mixed-citation></ref><ref id="bibr22-1076029619875520"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marginean</surname><given-names>A</given-names></name><name><surname>Banescu</surname><given-names>C</given-names></name><name><surname>Moldovan</surname><given-names>V</given-names></name></person-group>, <etal>et al.</etal>
<article-title>The impact of CYP2C19 loss-of-function polymorphisms, clinical, and
demographic variables on platelet response to clopidogrel evaluated using impedance
aggregometry</article-title>. <source>Clin Appl Thromb Hemost</source>.
<year>2017</year>;<volume>23</volume>(<issue>3</issue>):<fpage>255</fpage>&#x02013;<lpage>265</lpage>.
<comment>doi:10.1177/1076029616629211</comment>.<pub-id pub-id-type="pmid">26873108</pub-id></mixed-citation></ref><ref id="bibr23-1076029619875520"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rehman</surname><given-names>KU</given-names></name><name><surname>Akhtar</surname><given-names>T</given-names></name><name><surname>Sabar</surname><given-names>MF</given-names></name><name><surname>Tariq</surname><given-names>MA</given-names></name></person-group>
<article-title>Allele frequency distribution of CYP2C19*2 allelic
variants associated with clopidogrel resistance in cardiac patients</article-title>.
<source>Exp Ther Med</source>.
<year>2015</year>l;<volume>10</volume>(<issue>1</issue>):<fpage>309</fpage>&#x02013;<lpage>315</lpage>.<pub-id pub-id-type="pmid">26170954</pub-id></mixed-citation></ref><ref id="bibr24-1076029619875520"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fricke-Galindo</surname><given-names>I</given-names></name><name><surname>Cespedes-Garro</surname><given-names>C</given-names></name><name><surname>Rodrigues-Soares</surname><given-names>F</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Interethnic variation of CYP2C19 alleles, &#x02018;predicted&#x02019; phenotypes and
&#x02018;measured&#x02019; metabolic phenotypes across world populations</article-title>.
<source>Pharmacogenomics J</source>.
<year>2016</year>;<volume>16</volume>(<issue>2</issue>):<fpage>113</fpage>&#x02013;<lpage>123</lpage>.
<comment>doi:10.1038/tpj.2015.70</comment>.<pub-id pub-id-type="pmid">26503820</pub-id></mixed-citation></ref><ref id="bibr25-1076029619875520"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Peter</surname><given-names>I</given-names></name><name><surname>Scott</surname><given-names>SA</given-names></name></person-group>
<article-title>Pharmacogenetics in Jewish populations</article-title>.
<source>Drug Metabol Drug Interact</source>.
<year>2014</year>;<volume>29</volume>(<issue>4</issue>):<fpage>221</fpage>&#x02013;<lpage>233</lpage>.
<comment>doi:10.1515/dmdi-2013-0069</comment>.<pub-id pub-id-type="pmid">24867283</pub-id></mixed-citation></ref><ref id="bibr26-1076029619875520"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Azzam</surname><given-names>SI</given-names></name><name><surname>Alzoubi</surname><given-names>KH</given-names></name><name><surname>Khabour</surname><given-names>OF</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Factors that contribute to clopidogrel resistance in cardiovascular disease
patients: environmental and genetic approach</article-title>. <source>Int J Clin
Pharmacol Ther</source>.
<year>2013</year>;<volume>51</volume>(<issue>3</issue>):<fpage>179</fpage>&#x02013;<lpage>186</lpage>.
<comment>doi:10.5414/CP201784</comment>.<pub-id pub-id-type="pmid">23357840</pub-id></mixed-citation></ref><ref id="bibr27-1076029619875520"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kirac</surname><given-names>D</given-names></name><name><surname>Erdem</surname><given-names>A</given-names></name><name><surname>Avcilar</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Effects of genetic factors to stent thrombosis due to clopidogrel
resistance after coronary stent placement</article-title>. <source>Cell Mol Biol
(Noisy-le-grand)</source>.
<year>2016</year>;<volume>62</volume>(<issue>1</issue>):<fpage>51</fpage>&#x02013;<lpage>55</lpage>.</mixed-citation></ref><ref id="bibr28-1076029619875520"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saber</surname><given-names>MM</given-names></name><name><surname>Boroumand</surname><given-names>M</given-names></name><name><surname>Behmanesh</surname><given-names>M</given-names></name></person-group>
<article-title>Investigation of CYP2C19 allele and genotype frequencies
in Iranian population using experimental and computational approaches</article-title>.
<source>Thromb Res</source>.
<year>2014</year>;<volume>133</volume>(<issue>2</issue>):<fpage>272</fpage>&#x02013;<lpage>275</lpage>.
<comment>doi:10.1016/j.thromres.2013.11.005</comment>.<pub-id pub-id-type="pmid">24315317</pub-id></mixed-citation></ref><ref id="bibr29-1076029619875520"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zand</surname><given-names>N</given-names></name><name><surname>Tajik</surname><given-names>N</given-names></name><name><surname>Moghaddam</surname><given-names>AS</given-names></name><name><surname>Milanian</surname><given-names>I</given-names></name></person-group>
<article-title>Genetic polymorphisms of cytochrome P450 enzymes 2C9 and
2C19 in a healthy Iranian population</article-title>. <source>Clin Exp Pharmacol
Physiol</source>.
<year>2007</year>;<volume>34</volume>(<issue>1-2</issue>):<fpage>102</fpage>&#x02013;<lpage>105</lpage>.<pub-id pub-id-type="pmid">17201743</pub-id></mixed-citation></ref><ref id="bibr30-1076029619875520"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Azarpira</surname><given-names>N</given-names></name><name><surname>Namazi</surname><given-names>S</given-names></name><name><surname>Hendijani</surname><given-names>F</given-names></name><name><surname>Banan</surname><given-names>M</given-names></name><name><surname>Darai</surname><given-names>M</given-names></name></person-group>
<article-title>Investigation of allele and genotype frequencies of
CYP2C9, CYP2C19 and VKORC1 in Iran</article-title>. <source>Pharmacol Rep</source>.
<year>2010</year>;<volume>62</volume>(<issue>4</issue>):<fpage>740</fpage>&#x02013;<lpage>746</lpage>.<pub-id pub-id-type="pmid">20885015</pub-id></mixed-citation></ref><ref id="bibr31-1076029619875520"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Namazi</surname><given-names>S</given-names></name><name><surname>Kojuri</surname><given-names>J</given-names></name><name><surname>Khalili</surname><given-names>A</given-names></name><name><surname>Azarpira</surname><given-names>N</given-names></name></person-group>
<article-title>The impact of genetic polymorphisms of P2Y12, CYP3A5 and
CYP2C19 on clopidogrel response variability in Iranian patients</article-title>.
<source>Biochem Pharmacol</source>.
<year>2012</year>;<volume>83</volume>(<issue>7</issue>):<fpage>903</fpage>&#x02013;<lpage>908</lpage>.
<comment>doi:10.1016/j.bcp.2012.01.003</comment>.<pub-id pub-id-type="pmid">22265638</pub-id></mixed-citation></ref><ref id="bibr32-1076029619875520"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Payan</surname><given-names>M</given-names></name><name><surname>Tajik</surname><given-names>N</given-names></name><name><surname>Rouini</surname><given-names>MR</given-names></name><name><surname>Ghahremani</surname><given-names>MH</given-names></name></person-group>
<article-title>Genotype and allele frequency of CYP2C19*17 in a healthy
Iranian population</article-title>. <source>Med J Islam Repub Iran</source>.
<year>2015</year>;<volume>29</volume>:<fpage>269</fpage>.<pub-id pub-id-type="pmid">26793660</pub-id></mixed-citation></ref><ref id="bibr33-1076029619875520"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ghadam</surname><given-names>P</given-names></name><name><surname>Sadrai</surname><given-names>S</given-names></name><name><surname>Yousefi</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal>
<article-title>CYP2C19 polymorphism in Iranian patients receiving
clopidogrel</article-title>. <source>Genet Third Millennium</source>.
<year>2015</year>;<volume>13</volume>:<fpage>3940</fpage>&#x02013;<lpage>3944</lpage>.</mixed-citation></ref><ref id="bibr34-1076029619875520"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Jenoobi</surname><given-names>FI</given-names></name><name><surname>Alkharfy</surname><given-names>KM</given-names></name><name><surname>Alghamdi</surname><given-names>AM</given-names></name></person-group>, <etal>et al.</etal>
<article-title>CYP2C19 genetic polymorphism in Saudi Arabians</article-title>.
<source>Basic Clin Pharmacol Toxicol</source>.
<year>2013</year>;<volume>112</volume>(<issue>1</issue>):<fpage>50</fpage>&#x02013;<lpage>54</lpage>.
<comment>doi:10.1111/j.1742-7843.2012.00919.x</comment>.<pub-id pub-id-type="pmid">22747643</pub-id></mixed-citation></ref><ref id="bibr35-1076029619875520"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khalaf</surname><given-names>H</given-names></name><name><surname>Al Meman</surname><given-names>AA</given-names></name><name><surname>Rasool</surname><given-names>S</given-names></name></person-group>
<article-title>Impact of cytochrome P450 2C19*2 and *3 on clopidogrel
loading dose in Saudi patients with acute coronary syndrome</article-title>.
<source>Drug Metab Lett</source>.
<year>2016</year>;<volume>10</volume>(<issue>1</issue>):<fpage>65</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">26573281</pub-id></mixed-citation></ref><ref id="bibr36-1076029619875520"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khalil</surname><given-names>BM</given-names></name><name><surname>Shahin</surname><given-names>MH</given-names></name><name><surname>Solayman</surname><given-names>MH</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Genetic and nongenetic factors affecting clopidogrel response in the
Egyptian population</article-title>. <source>Clin Transl Sci</source>.
<year>2016</year>;<volume>9</volume>(<issue>1</issue>):<fpage>23</fpage>&#x02013;<lpage>28</lpage>.
<comment>doi:10.1111/cts.12383</comment>.<pub-id pub-id-type="pmid">26757134</pub-id></mixed-citation></ref><ref id="bibr37-1076029619875520"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Djaffar Jureidini</surname><given-names>I</given-names></name><name><surname>Chamseddine</surname><given-names>N</given-names></name><name><surname>Keleshian</surname><given-names>S</given-names></name><name><surname>Naoufal</surname><given-names>R</given-names></name><name><surname>Zahed</surname><given-names>L</given-names></name><name><surname>Hakime</surname><given-names>N</given-names></name></person-group>
<article-title>Prevalence of CYP2C19 polymorphisms in the Lebanese
population</article-title>. <source>Mol Biol Rep</source>.
<year>2011</year>;<volume>38</volume>(<issue>8</issue>):<fpage>5449</fpage>&#x02013;<lpage>5452</lpage>.
<comment>doi:10.1007/s11033-011-0700-y</comment>.<pub-id pub-id-type="pmid">21380557</pub-id></mixed-citation></ref><ref id="bibr38-1076029619875520"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nassar</surname><given-names>S</given-names></name><name><surname>Amro</surname><given-names>O</given-names></name><name><surname>Abu-Rmaileh</surname><given-names>H</given-names></name><name><surname>Alshaer</surname><given-names>I</given-names></name><name><surname>KorachiAyesh</surname><given-names>SM</given-names></name></person-group>
<article-title>ABCB1 C3435 T and CYP2C19*2 polymorphisms in a Palestinian
and Turkish population: a pharmacogenetic perspective to clopidogrel</article-title>.
<source>Meta Gene</source>.
<year>2014</year>;<volume>2</volume>:<fpage>314</fpage>&#x02013;<lpage>319</lpage>.
<comment>doi:10.1016/j.mgene.2014.01.009</comment>.<pub-id pub-id-type="pmid">25606414</pub-id></mixed-citation></ref><ref id="bibr39-1076029619875520"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saeed</surname><given-names>LH</given-names></name><name><surname>Mayet</surname><given-names>AY</given-names></name></person-group>
<article-title>Genotype-phenotype analysis of CYP2C19 in healthy Saudi
individuals and its potential clinical implication in drug therapy</article-title>.
<source>Int J Med Sci</source>.
<year>2013</year>;<volume>10</volume>(<issue>11</issue>):<fpage>1497</fpage>&#x02013;<lpage>1502</lpage>.
<comment>doi:10.7150/ijms.6795</comment>.<pub-id pub-id-type="pmid">24046523</pub-id></mixed-citation></ref><ref id="bibr40-1076029619875520"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alhazzani</surname><given-names>AA</given-names></name><name><surname>Munisamy</surname><given-names>M</given-names></name><name><surname>Karunakaran</surname><given-names>G</given-names></name></person-group>
<article-title>Pharmacogenetics of CYP2C19 genetic polymorphism on
clopidogrel response in patients with ischemic stroke from Saudi Arabia</article-title>.
<source>Neurosciences (Riyadh)</source>.
<year>2017</year>;<volume>22</volume>(<issue>1</issue>):<fpage>31</fpage>&#x02013;<lpage>37</lpage>.
<comment>doi:10.17712/nsj.2017.1.20160303</comment>.<pub-id pub-id-type="pmid">28064328</pub-id></mixed-citation></ref><ref id="bibr41-1076029619875520"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sen</surname><given-names>HM</given-names></name><name><surname>Silan</surname><given-names>F</given-names></name><name><surname>Silan</surname><given-names>C</given-names></name><name><surname>Degirmenci</surname><given-names>Y</given-names></name><name><surname>Ozisik Kamaran</surname><given-names>HI</given-names></name></person-group>
<article-title>Effects of CYP2C19 and P2Y12 gene polymorphisms on
clinical results of patients using clopidogrel after acute ischemic cerebrovascular
disease</article-title>. <source>Balkan J Med Genet</source>.
<year>2015</year>;<volume>17</volume>(<issue>2</issue>):<fpage>37</fpage>&#x02013;<lpage>41</lpage>.
<comment>doi:10.2478/bjmg-2014-0072</comment>.<pub-id pub-id-type="pmid">25937796</pub-id></mixed-citation></ref><ref id="bibr42-1076029619875520"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akhlaghi</surname><given-names>A</given-names></name><name><surname>Shirani</surname><given-names>S</given-names></name><name><surname>Ziaie</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Cytochrome P450 2C19 polymorphism in iranian patients with coronary artery
disease</article-title>. <source>ARYA Atheroscler</source>.
<year>2011</year>;<volume>7</volume>(<issue>3</issue>):<fpage>106</fpage>&#x02013;<lpage>110</lpage>.<pub-id pub-id-type="pmid">22577456</pub-id></mixed-citation></ref><ref id="bibr43-1076029619875520"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saydam</surname><given-names>F</given-names></name><name><surname>Degirmenci</surname><given-names>I</given-names></name><name><surname>Birdane</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal>
<article-title>The CYP2C19*2 and CYP2C19*17 polymorphisms play a vital role in clopidogrel
responsiveness after percutaneous coronary intervention: a pharmacogenomics
study</article-title>. <source>Basic Clin Pharmacol Toxicol</source>.
<year>2017</year>;<volume>121</volume>(<issue>1</issue>):<fpage>29</fpage>&#x02013;<lpage>36</lpage>.
<comment>doi:10.1111/bcpt.12763</comment>
<pub-id pub-id-type="pmid">28135763</pub-id></mixed-citation></ref><ref id="bibr44-1076029619875520"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nozari</surname><given-names>Y</given-names></name><name><surname>Vosooghi</surname><given-names>S</given-names></name><name><surname>Boroumand</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal>
<article-title>The impact of cytochrome P450 2C19 polymorphism on the occurrence of
one-year in-stent restenosis in patients who underwent percutaneous coronary
intervention: a case-match study</article-title>. <source>Anatol J Cardiol</source>.
<year>2015</year>;<volume>15</volume>(<issue>5</issue>):<fpage>348</fpage>&#x02013;<lpage>353</lpage>.
<comment>doi:10.5152/akd.2014.5418</comment>.<pub-id pub-id-type="pmid">25993709</pub-id></mixed-citation></ref><ref id="bibr45-1076029619875520"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sivadas</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Scaria</surname><given-names>V</given-names></name></person-group>
<article-title>Landscape of warfarin and clopidogrel pharmacogenetic
variants in Qatari population from whole exome datasets</article-title>.
<source>Pharmacogenomics</source>.
<year>2016</year>;<volume>17</volume>(<issue>17</issue>):<fpage>1891</fpage>&#x02013;<lpage>1901</lpage>.
<comment>doi:10.2217/pgs-2016-0130</comment>.<pub-id pub-id-type="pmid">27767380</pub-id></mixed-citation></ref><ref id="bibr46-1076029619875520"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Simon</surname><given-names>T</given-names></name><name><surname>Verstuyft</surname><given-names>C</given-names></name><name><surname>Mary-Krause</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Genetic determinants of response to clopidogrel and cardiovascular
events</article-title>. <source>N Engl J Med</source>.
<year>2009</year>;<volume>360</volume>(<issue>4</issue>):<fpage>363</fpage>&#x02013;<lpage>375</lpage>.
<comment>doi:10.1056/NEJMoa0808227</comment>.<pub-id pub-id-type="pmid">19106083</pub-id></mixed-citation></ref><ref id="bibr47-1076029619875520"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marcucci</surname><given-names>R</given-names></name><name><surname>Gori</surname><given-names>AM</given-names></name><name><surname>Paniccia</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Cardiovascular death and nonfatal myocardial infarction in acute coronary
syndrome patients receiving coronary stenting are predicted by residual platelet
reactivity to ADP detected by a point-of-care assay: a 12-month
follow-up</article-title>. <source>Circulation</source>.
<year>2009</year>;<volume>119</volume>(<issue>2</issue>):<fpage>237</fpage>&#x02013;<lpage>242</lpage>.
<comment>doi:10.1161/CIRCULATIONAHA.108.812636</comment>.<pub-id pub-id-type="pmid">19118249</pub-id></mixed-citation></ref><ref id="bibr48-1076029619875520"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Uzun</surname><given-names>F</given-names></name><name><surname>Biyik</surname><given-names>I</given-names></name><name><surname>Akturk</surname><given-names>IF</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Antiplatelet resistance and the role of associated variables in stable
patients treated with stenting</article-title>. <source>Postepy Kardiol
Interwencyjnej</source>.
<year>2015</year>;<volume>11</volume>(<issue>1</issue>):<fpage>19</fpage>&#x02013;<lpage>25</lpage>.
<comment>doi:10.5114/pwki.2015.49180</comment>.<pub-id pub-id-type="pmid">25848366</pub-id></mixed-citation></ref><ref id="bibr49-1076029619875520"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berger</surname><given-names>JS</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name></person-group>, <etal>et al.</etal>
<article-title>The relative efficacy and safety of clopidogrel in women and men a
sex-specific collaborative meta-analysis</article-title>. <source>J Am Coll
Cardiol</source>.
<year>2009</year>;<volume>54</volume>(<issue>21</issue>):<fpage>1935</fpage>&#x02013;<lpage>1945</lpage>.
<comment>doi:10.1016/j.jacc.2009.05.074</comment>.<pub-id pub-id-type="pmid">19909874</pub-id></mixed-citation></ref><ref id="bibr50-1076029619875520"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siller-Matula</surname><given-names>JM</given-names></name><name><surname>Lang</surname><given-names>I</given-names></name><name><surname>Christ</surname><given-names>G</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name></person-group>
<article-title>Calcium-channel blockers reduce the antiplatelet effect of
clopidogrel</article-title>. <source>J Am Coll Cardiol</source>.
<year>2008</year>;<volume>52</volume>(<issue>19</issue>):<fpage>1557</fpage>&#x02013;<lpage>1563</lpage>.
<comment>doi:10.1016/j.jacc.2008.07.055</comment>.<pub-id pub-id-type="pmid">19007592</pub-id></mixed-citation></ref><ref id="bibr51-1076029619875520"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gremmel</surname><given-names>T</given-names></name><name><surname>Steiner</surname><given-names>S</given-names></name><name><surname>Seidinger</surname><given-names>D</given-names></name><name><surname>Koppensteiner</surname><given-names>R</given-names></name><name><surname>Panzer</surname><given-names>S</given-names></name><name><surname>Kopp</surname><given-names>CW</given-names></name></person-group>
<article-title>Calcium-channel blockers decrease clopidogrel-mediated
platelet inhibition</article-title>. <source>Heart</source>.
<year>2010</year>;<volume>96</volume>(<issue>3</issue>):<fpage>186</fpage>&#x02013;<lpage>189</lpage>.
<comment>doi:10.1136/hrt.2009.171488</comment>.<pub-id pub-id-type="pmid">19687016</pub-id></mixed-citation></ref><ref id="bibr52-1076029619875520"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katoh</surname><given-names>M</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Shimada</surname><given-names>N</given-names></name><name><surname>Yamazaki</surname><given-names>H</given-names></name><name><surname>Yokoi</surname><given-names>T</given-names></name></person-group>
<article-title>Inhibition of human cytochrome P450 enzymes by
1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug
interactions</article-title>. <source>Eur J Clin Pharmacol</source>.
<year>2000</year>;<volume>55</volume>(<issue>11-12</issue>):<fpage>843</fpage>&#x02013;<lpage>852</lpage>.<pub-id pub-id-type="pmid">10805063</pub-id></mixed-citation></ref><ref id="bibr53-1076029619875520"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paravattil</surname><given-names>B</given-names></name><name><surname>Elewa</surname><given-names>H</given-names></name></person-group>
<article-title>Strategies to optimize dual antiplatelet therapy after
coronary artery stenting in acute coronary syndrome</article-title>. <source>J
Cardiovasc Pharmacol Ther</source>.
<year>2017</year>;<volume>22</volume>(<issue>4</issue>):<fpage>347</fpage>&#x02013;<lpage>355</lpage>.
<comment>doi:10.1177/1074248416683048</comment>.<pub-id pub-id-type="pmid">28587584</pub-id></mixed-citation></ref><ref id="bibr54-1076029619875520"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Esteve-Pastor</surname><given-names>MA</given-names></name><name><surname>Ruiz-Nodar</surname><given-names>JM</given-names></name><name><surname>Orenes-Pinero</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Temporal trends in the use of antiplatelet therapy in patients with acute
coronary syndromes</article-title>. <source>J Cardiovasc Pharmacol Ther</source>.
<year>2018</year>;<volume>23</volume>(<issue>1</issue>):<fpage>57</fpage>&#x02013;<lpage>65</lpage>.
<comment>doi:10.1177/1074248417724869</comment>.<pub-id pub-id-type="pmid">28789568</pub-id></mixed-citation></ref><ref id="bibr55-1076029619875520"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wiviott</surname><given-names>SD</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>McCabe</surname><given-names>CH</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Prasugrel versus clopidogrel in patients with acute coronary
syndromes</article-title>. <source>N Engl J Med</source>.
<year>2007</year>;<volume>357</volume>:<fpage>2001</fpage>&#x02013;<lpage>2015</lpage>.<pub-id pub-id-type="pmid">17982182</pub-id></mixed-citation></ref><ref id="bibr56-1076029619875520"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wallentin</surname><given-names>L</given-names></name><name><surname>Becker</surname><given-names>RC</given-names></name><name><surname>Budaj</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Ticagrelor versus clopidogrel in patients with acute coronary
syndromes</article-title>. <source>N Engl J Med</source>.
<year>2009</year>;<volume>361</volume>(<issue>11</issue>):<fpage>1045</fpage>&#x02013;<lpage>1057</lpage>.
<comment>doi:10.1056/NEJMoa0904327</comment>.<pub-id pub-id-type="pmid">19717846</pub-id></mixed-citation></ref><ref id="bibr57-1076029619875520"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mega</surname><given-names>JL</given-names></name><name><surname>Hochholzer</surname><given-names>W</given-names></name><name><surname>Frelinger</surname><given-names>AL</given-names><suffix>3rd</suffix></name></person-group>, <etal>et al.</etal>
<article-title>Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet
reactivity in patients with stable cardiovascular disease</article-title>.
<source>JAMA</source>.
<year>2011</year>;<volume>306</volume>(<issue>20</issue>):<fpage>2221</fpage>&#x02013;<lpage>2228</lpage>.
<comment>doi:10.1001/jama.2011.1703</comment>.<pub-id pub-id-type="pmid">22088980</pub-id></mixed-citation></ref></ref-list></back></article>